Search results for "lymphoma."

showing 10 items of 697 documents

Clinical and endoscopic presentation of primary gastric lymphoma: a multicentre study

2006

1. Aliment Pharmacol Ther. 2006 Mar 15;23(6):721-6. Clinical and endoscopic presentation of primary gastric lymphoma: a multicentre study. Andriani A, Zullo A, Di Raimondo F, Patti C, Tedeschi L, Recine U, Caruso L, Bonanno G, Chiarenza A, Lizzani G, Miedico A, Romanelli A, Costa A, Linea C, Marrone C, Mirto S, Mistretta A, Montalbano L, Restivo G, Vinci M, Bibas M, Hassan C, Stella F, Cottone M, Morini S. Department of Haematology and Gastroenterology, 'San Giacomo' and 'Nuovo Regina Margherita' Hospitals, Rome, Italy. BACKGROUND: Although the stomach is the most frequent site of intestinal lymphomas, few data are available on both clinical endoscopic presentation of gastric lymphoma and p…

Malegastric lymphoma.helicobactermedicine.medical_specialtyLymphomaSettore MED/12 - GASTROENTEROLOGIAGastroenterologyEndoscopy GastrointestinalHelicobacter Infectionsimmune system diseasesStomach Neoplasmshemic and lymphatic diseasesInternal medicinemedicineGastric mucosaHumansPharmacology (medical)AntrumNeoplasm StagingRetrospective StudiesHepatologymedicine.diagnostic_testbiologyHelicobacter pyloribusiness.industryGastric lymphomaStomachStomachGastroenterologyRetrospective cohort studyHelicobacter pyloriMiddle Agedmedicine.diseasebiology.organism_classificationEndoscopyLymphomamedicine.anatomical_structureGastric MucosaFemalebusiness
researchProduct

Synergistic effect of peplomycin in combination with bleomycin on L5178y mouse lymphoma cells in vivo.

1984

Studying the treatment of NMRI mice with ip injections of bleomycin (BLM) for 5 days we found an approximate LD50 of 35 mg/kg; the toxicity of peplomycin (PEP) was slightly higher (LD50: approximately 25 mg/kg). The effect of the two drugs on growth of L5178y mouse lymphoma cells in NMRI mice was examined. BLM alone caused at a concentration of 2.5 mg/kg an almost complete inhibition of tumor cell growth; the same effect was determined with 1 mg PEP/kg. At these concentrations the drugs caused an increase of the survival time of 110% (BLM) or 104% (PEP). Given in combination, one-sixth of the optimal doses yielded an 100% increase of the median survival time. These results indicate a signif…

Malemedicine.drug_classCell SurvivalAntibioticsPharmacologyBiologyBleomycinchemistry.chemical_compoundBleomycinMicePeplomycinIn vivoDrug DiscoveryAntineoplastic Combined Chemotherapy ProtocolsmedicineAnimalsLeukemia L5178PharmacologyLeukemia Experimentalurogenital systemCell growthMouse LymphomaBiological activityDrug SynergismchemistryToxicityImmunologyPeplomycinThe Journal of antibiotics
researchProduct

Cancer in the older person.

2005

Cancer in the older person is an increasingly common problem, due to the progressive prolongation of the life-expectancy of the Western population. This article reviews the mechanisms associating aging and cancer, age-related changes in cancer biology, assessment of the older person to estimate life-expectancy, treatment tolerance, and medical and social conditions that may interfere with cancer treatment, effectiveness of cancer prevention and cancer treatment in older individuals. A comprehensive geriatric assessment (CGA) is commonly used to predict life-expectancy and functional reserve and to unearth conditions that may jeopardize cancer prevention and treatment. In the interest of cos…

Malemedicine.medical_specialtyColorectal cancerPopulationPRIMARY-CARE PATIENTSPainDiseaseProstate cancerNeoplasmsMedicineHumansPain ManagementRadiology Nuclear Medicine and imagingNON-HODGKINS-LYMPHOMAIntensive care medicineeducationELDERLY-PATIENTSGeriatric AssessmentSURGICAL ADJUVANT BREASTPreventive healthcareAgededucation.field_of_studyCancer preventionbusiness.industryCOMPREHENSIVE GERIATRIC ASSESSMENTCancerGeneral MedicineRANDOMIZED CONTROLLED-TRIALCOLONY-STIMULATING FACTORmedicine.diseasePROSTATE-CANCERClinical trialOncologyCOOPERATIVE-ONCOLOGY-GROUPPhysical therapyDIFFUSE HISTIOCYTIC LYMPHOMAFemalebusinessCancer treatment reviews
researchProduct

Treatment of relapse after allogeneic stem cell transplantation in children and adolescents with ALL: the Frankfurt experience

2016

Therapy for post-transplant relapse of paediatric ALL is limited. Standardised curative approaches are not available. We hereby describe our local procedure in this life-threatening situation. A total of 101 ALL patients received their first allogeneic stem cell transplantation (SCT) in our institution. After relapse, our primary therapeutic goal was to cure the patient with high-dose chemotherapy or specific immunotherapy (HDCHT/SIT) followed by a second SCT from a haploidentical donor (transplant approach). If this was not feasible, low-dose chemotherapy and donor lymphocyte infusions (LDCHT+DLI) were offered (non-transplant approach). A total of 23 patients suffered a post-transplant rel…

Malemedicine.medical_specialtyLymphocyte TransfusionAdolescentmedicine.medical_treatment03 medical and health sciences0302 clinical medicineRecurrenceGermanymedicineHumansProgenitor cellChildRetrospective StudiesTransplantationChemotherapybusiness.industryInfantRetrospective cohort studyHematologyImmunotherapyPrecursor Cell Lymphoblastic Leukemia-LymphomaAllograftsmedicine.diseaseTissue DonorsSurgeryTransplantationClinical trialsurgical procedures operativeGraft-versus-host diseaseChild PreschoolLymphocyte Transfusion030220 oncology & carcinogenesisFemaleImmunotherapybusinessStem Cell Transplantation030215 immunologyBone Marrow Transplantation
researchProduct

Efficacy and safety of yttrium 90 ibritumomab tiuxetan in patients with relapsed or refractory diffuse large B-cell lymphoma not appropriate for auto…

2007

A prospective, multicenter, nonrandomized phase 2 trial was conducted to evaluate the efficacy and safety of a single dose of yttrium-90 (90Y) ibritumomab tiuxetan in elderly patients in first relapsed or primary refractory diffuse large B-cell lymphoma (DLBCL) ineligible for stem-cell transplantation. Patients had been previously treated with chemotherapy (group A, n = 76) or chemotherapy plus rituximab (group B, n = 28). Patients in group A were further divided into patients in whom induction therapy had failed (stratum AI, n = 33) and patients who had relapsed after achieving complete response (CR; stratum AII, n = 43). The overall response rate (ORR) was 52% and 53% in strata AI and AII…

Malemedicine.medical_specialtyLymphoma B-Cellmedicine.medical_treatmentImmunologyIbritumomab tiuxetanSalvage therapyAuthor Keywords:RadioimmunotherapyBiochemistryGastroenterologyAntibodies Monoclonal Murine-DerivedTRIAL Author InformationAutologous stem-cell transplantationRecurrenceInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineRefractory Diffuse Large B-Cell LymphomaHumansYttrium RadioisotopesY-90-ibritumomab tiuxetanHematologic toxicity KeyWords Plus:B-CELL LYMPHOMAAuthor Keywords:Radioimmunotherapy; Y-90-ibritumomab tiuxetan; Hematologic toxicity KeyWords Plus:B-CELL LYMPHOMA; LOW-GRADE; RADIOIMMUNOTHERAPY; INDOLENT; TRIAL Author InformationAgedCerebral HemorrhageAged 80 and overSalvage TherapyChemotherapybusiness.industryRemission InductionAntibodies MonoclonalCell BiologyHematologyRADIOIMMUNOTHERAPYINDOLENTmedicine.diseaseSurvival AnalysisLOW-GRADESurgeryTransplantationRituximabFemaleLymphoma Large B-Cell DiffusebusinessRituximabDiffuse large B-cell lymphomamedicine.drug
researchProduct

Childhood high-risk acute lymphoblastic leukemia in first remission: results after chemotherapy or transplant from the AIEOP ALL 2000 study

2014

The outcome of high-risk (HR) Acute Lymphoblastic Leukemia (ALL) patients enrolled in AIEOP-BFM ALL 2000 study (NCT00613457) in Italy is described. Overall, 1999 Philadelphia negative ALL patients entered the study. HR criteria were: minimal residual disease (MRD) levels ≥10-3 at day 78 (HR-MRD), no complete remission (no-CR) at day 33, t(4;11) translocation, Prednisone Poor Response (PPR). Treatment (2 years) included protocol I, 3 polychemotherapy blocks, delayed intensification (protocol IIx2 or IIIx3), cranial radiotherapy, maintenance. 312 HR patients (15.6% of the total) had 5-year event-free survival (EFS) and overall survival (OS) of 58.9%(SE 2.8) and 68.9%(2.6). In hierarchical ord…

Malemedicine.medical_specialtyNeoplasm ResidualAdolescentmedicine.medical_treatmentImmunologyChromosomal translocationhigh riskacute lymphoblastic leukemiaHematopoietic stem cell transplantationBiochemistryGastroenterologyAdolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child Preschool; Combined Modality Therapy; Female; Hematopoietic Stem Cell Transplantation; Humans; Infant; Male; Neoplasm Residual; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Radiotherapy; Remission Induction; Treatment Outcome; Hematology; Biochemistry; Cell Biology; ImmunologyPrednisonehemic and lymphatic diseasesInternal medicineAntineoplastic Combined Chemotherapy Protocolshigh risk; acute lymphoblastic leukemiaHumansMedicineNeoplasmPreschoolChildChemotherapyAntineoplastic Combined Chemotherapy ProtocolRadiotherapybusiness.industryRemission InductionHematopoietic Stem Cell TransplantationInfantCell BiologyHematologyPrecursor Cell Lymphoblastic Leukemia-Lymphomamedicine.diseaseCombined Modality TherapyMinimal residual diseaseSurgeryClinical trialRadiation therapyTreatment OutcomeN/ASettore MED/38 - PEDIATRIA GENERALE E SPECIALISTICAResidualChild PreschoolNeoplasmFemalebusinessHumanmedicine.drugBlood
researchProduct

Lymphoma occurring in patients over 90 years of age: characteristics, outcomes, and prognostic factors. A retrospective analysis of 234 cases from th…

2013

International audience; BACKGROUND: Lymphoma occurring in patients aged 90 or older is not uncommon, and its incidence is expected to increase over time. Management of these patients is difficult given their underlying fragility and the lack of information regarding this population. PATIENTS AND METHODS: We retrospectively analyzed 234 patients diagnosed with lymphoma at the age of 90 years or older (90+) between 1990 and 2012 to describe their characteristics, management, outcomes and prognostic factors. RESULTS: The median age was 92 years; 88% were B-cell lymphomas consisting mainly in diffuse large B-cell lymphoma. The median overall survival (OS) was 7.2 months (range, 0-92 months) for…

Malemedicine.medical_specialtyPalliative careSurvivalPopulation[SDV.CAN]Life Sciences [q-bio]/Cancerlymphoma[ SDV.CAN ] Life Sciences [q-bio]/Cancer03 medical and health sciences0302 clinical medicine[SDV.CAN] Life Sciences [q-bio]/Cancerimmune system diseasesInternal medicinehemic and lymphatic diseasesAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansHypoalbuminemiaeducationSerum Albumin030304 developmental biologyCause of deathRetrospective StudiesAged 80 and over0303 health scienceseducation.field_of_studypalliative carebusiness.industryIncidence (epidemiology)IncidenceLymphoma Non-HodgkinHematologymedicine.diseasePrognosisComorbidity3. Good healthLymphomaSurgeryaged 80 and overcomorbidityOncology030220 oncology & carcinogenesisFemaleLymphoma Large B-Cell DiffusebusinessDiffuse large B-cell lymphoma
researchProduct

Incidence of hematologic malignancies in Europe by morphologic subtype: Results of the HAEMACARE project

2010

AbstractChanging definitions and classifications of hematologic malignancies (HMs) complicate incidence comparisons. HAEMACARE classified HMs into groupings consistent with the latest World Health Organization classification and useful for epidemiologic and public health purposes. We present crude, age-specific and age-standardized incidence rates for European HMs according to these groupings, estimated from 66 371 lymphoid malignancies (LMs) and 21 796 myeloid malignancies (MMs) registered in 2000-2002 by 44 European cancer registries, grouped into 5 regions. Age-standardized incidence rates were 24.5 (per 100 000) for LMs and 7.55 for MMs. The commonest LMs were plasma cell neoplasms (4.6…

Malemedicine.medical_specialtyPathologyChildhood leukemiaHematologic malignant; Europe; morphologic subtype; international comparison; population-based cancer registry.ImmunologyPopulationUNITED-STATESALCOHOLBiochemistryNOMyelodysplastic–myeloproliferative diseasesInternal medicineEpidemiologymorphologymedicineLYMPHOMAHumansEPIDEMIOLOGYRegistriesEXPOSUREeducationRISKeducation.field_of_studyTOBACCOhaematologic malignanciesbusiness.industryIncidence (epidemiology)IncidenceleukemiaMyeloid leukemiaCell BiologyHematologyHematologic malignancies; morphology; Europe.Plasma cell neoplasmmedicine.diseaseMyelodysplastic-Myeloproliferative DiseasesLymphomaEuropeCANCER INCIDENCEHematologic Neoplasmscancer incidence tobacco alcohol epidemiology leukemia risk exposureCHILDHOOD LEUKEMIAHematologic malignanciesFemalebusiness
researchProduct

Survival of Mycosis Fungoides in Patients in the Southeast of England

2004

<i>Background:</i> Mycosis fungoides (MF) is the most common skin lymphoma. The aetiology of MF remains unknown, and no therapy has to date significantly altered patient survival. <i>Objective:</i> The present study examines trends in survival of MF patients in a well-defined population-based disease group, namely patients registered over a 40-year period at the Thames Cancer Registry, Southeast England. <i>Methods:</i> The Thames Cancer Registry is a population-based registry, covering a population of approximately 14 million people. Data were taken from the Surveillance, Epidemiology and End Results cancer registry programme and the National Centre for …

Malemedicine.medical_specialtyPathologySkin NeoplasmsAntineoplastic Agents HormonalDermatologyCohort StudiesMycosis FungoidesSex FactorsResidence CharacteristicsEpidemiologymedicineHumansSezary SyndromeIn patientRegistriesSurvival rateAgedProportional Hazards ModelsMycosis fungoidesbusiness.industryProportional hazards modelAge FactorsMiddle AgedPrognosismedicine.diseaseDermatologyPeripheral T-cell lymphomaLymphomaSurvival RateEnglandPopulation SurveillanceEtiologyFemalebusinessFollow-Up StudiesSEER Program
researchProduct

Linfomas malignos primários nas glandulas salivares

2011

Primary malignant lymphomas in the salivary glands are relatively rare. Clinical presentation is not characteristic and the disease is often overlooked resulting in diagnosis and treatment delays. AIM: To stress the importance of the diagnostic process and combined management, we present a series of eight patients with malignant lymphoma of the parotid who were diagnosed only after surgery and managed with radiation and chemotherapy. METHODS: Retrospective series of patients with primary malignant lymphoma of the parotid gland managed with radiotherapy and diagnostic surgical partial resection. RESULTS: After treatment completion we achieved a loco-regional control rate of 87.5%. Toxicity w…

Malemedicine.medical_specialtyPathologyglândulas salivaresSettore MED/06 - Oncologia Medicamedicine.medical_treatmentsalivary glandsSettore MED/19 - Chirurgia PlasticalymphomaDiseaseradioterapiaSettore MED/29 - Chirurgia Maxillofaccialestomatognathic systemlymphoma parotid salivary gland non-Hodgkin surgeryHumansMedicineStage (cooking)linfomalinfoma não hodgkinradiotherapyneoplasias parotídeasAgedRetrospective StudiesAged 80 and overPharmacologyChemotherapybusiness.industryLymphoma Non-HodgkinRate controlMiddle AgedPartial resectionmedicine.diseaseCombined Modality Therapynon-hodgkinLymphomaParotid glandRadiation therapyparotid neoplasmsTreatment Outcomemedicine.anatomical_structureSettore MED/31 - OtorinolaringoiatriaFemaleRadiologybusiness
researchProduct